Get started
Work

Abstract C031: A randomized Phase 1b study of IGM-8444 in combination with FOLFIRI + bevacizumab compared to FOLFIRI + bevacizumab alone in second line metastatic colorectal cancer

Year: 2023
Type: conference-abstract
DOI: 10.1158/1535-7163.targ-23-c031
Authors: Susanna Ulahannan, Meredith Pelster, Patricia LoRusso, Gerald Falchook, Judy Wang, Minal Barve, Jaspreet Grewal, Warren Chow, Jason Henry, Michael Cecchini, Vivek Subbiah, Maya Leabman, Genevive Hernandez, Yao Li, Angus Sinclair, Beatrice Wang, Maya Kotturi, Eric Humke, Sean Ahern, Leslie Ennis, Melaine Caruano, Sapeck Agrawal
Institutions: University of Oklahoma Health Sciences Center, Sarah Cannon, Yale Cancer Center, Yale University, HealthONE, Mary Crowley Cancer Research Center, Norton Healthcare, IGM Biosciences (United States)
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: closed
OpenAlex ID: W4389239793
Cites:
Cited by: 2
Related to: 10